カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

NASH（非アルコール性脂肪性肝炎）バイオマーカーの世界市場2022：血清バイオマーカー、肝線維症バイオマーカー、アポトーシスバイオマーカー、酸化ストレスバイオマーカー、その他

◆英語タイトル：Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22DC3552）◆商品コード：GIR22DC3552
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2023年1月
◆ページ数：97
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥522,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥783,000見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,044,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

世界のNASH（非アルコール性脂肪性肝炎）バイオマーカー市場レポートは、グローバル市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
Global Info Research社の最新のリサーチによると、世界のNASH（非アルコール性脂肪性肝炎）バイオマーカーの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

NASH（非アルコール性脂肪性肝炎）バイオマーカー市場はタイプとアプリケーションによって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメントは次をカバーします。
・血清バイオマーカー、肝線維症バイオマーカー、アポトーシスバイオマーカー、酸化ストレスバイオマーカー、その他

アプリケーション別セグメントは次のように区分されます。
・製薬及びCRO業界、病院、診断ラボ、学術研究機関

世界のNASH（非アルコール性脂肪性肝炎）バイオマーカー市場の主要な市場プレーヤーは以下のとおりです。
・GENFIT SA、Gilead Sciences, Inc. (GILD)、AstraZeneca、Novartis AG、Bristol-Myers Squibb Company、Allergan Plc、Novo Nordisk A/S、Boehringer Ingelheim、Pfizer Inc

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・欧州（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南米（ブラジル、アルゼンチン、コロンビア）
・中東/アフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査資料の内容は計15章あります。
・第1章では、NASH（非アルコール性脂肪性肝炎）バイオマーカー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なNASH（非アルコール性脂肪性肝炎）バイオマーカーメーカーの企業概要、2019年～2022年までのNASH（非アルコール性脂肪性肝炎）バイオマーカーの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なNASH（非アルコール性脂肪性肝炎）バイオマーカーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別NASH（非アルコール性脂肪性肝炎）バイオマーカーの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのNASH（非アルコール性脂肪性肝炎）バイオマーカーの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのNASH（非アルコール性脂肪性肝炎）バイオマーカー市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびNASH（非アルコール性脂肪性肝炎）バイオマーカーの産業チェーンを掲載しています。
・第13、14、15章では、NASH（非アルコール性脂肪性肝炎）バイオマーカーの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
– NASH（非アルコール性脂肪性肝炎）バイオマーカーの概要
– 種類別分析（2017年vs2021年vs2028年）：血清バイオマーカー、肝線維症バイオマーカー、アポトーシスバイオマーカー、酸化ストレスバイオマーカー、その他
– 用途別分析（2017年vs2021年vs2028年）：製薬及びCRO業界、病院、診断ラボ、学術研究機関
– 世界のNASH（非アルコール性脂肪性肝炎）バイオマーカー市場規模・予測
– 世界のNASH（非アルコール性脂肪性肝炎）バイオマーカー生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– GENFIT SA、Gilead Sciences, Inc. (GILD)、AstraZeneca、Novartis AG、Bristol-Myers Squibb Company、Allergan Plc、Novo Nordisk A/S、Boehringer Ingelheim、Pfizer Inc
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：血清バイオマーカー、肝線維症バイオマーカー、アポトーシスバイオマーカー、酸化ストレスバイオマーカー、その他
・用途別分析2017年-2028年：製薬及びCRO業界、病院、診断ラボ、学術研究機関
・NASH（非アルコール性脂肪性肝炎）バイオマーカーの北米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・NASH（非アルコール性脂肪性肝炎）バイオマーカーのヨーロッパ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・NASH（非アルコール性脂肪性肝炎）バイオマーカーのアジア市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・NASH（非アルコール性脂肪性肝炎）バイオマーカーの南米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・NASH（非アルコール性脂肪性肝炎）バイオマーカーの中東・アフリカ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

❖ レポートの目次 ❖

1 Market Overview
1.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Serum Biomarkers
1.2.3 Hepatic Fibrosis Biomarkers
1.2.4 Apoptosis Biomarkers
1.2.5 Oxidative Stress Biomarkers
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Pharma & CRO Industry
1.3.3 Hospitals
1.3.4 Diagnostic Labs
1.3.5 Academic Research Institutes
1.4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size & Forecast
1.4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value (2017 & 2021 & 2028)
1.4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume (2017-2028)
1.4.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (2017-2028)
1.5 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity Analysis
1.5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Total Production Capacity (2017-2028)
1.5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers
1.6.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints
1.6.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Trends Analysis
2 Manufacturers Profiles
2.1 GENFIT SA
2.1.1 GENFIT SA Details
2.1.2 GENFIT SA Major Business
2.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.1.4 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Gilead Sciences, Inc. (GILD)
2.2.1 Gilead Sciences, Inc. (GILD) Details
2.2.2 Gilead Sciences, Inc. (GILD) Major Business
2.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.2.4 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.3.4 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.4.4 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Bristol-Myers Squibb Company
2.5.1 Bristol-Myers Squibb Company Details
2.5.2 Bristol-Myers Squibb Company Major Business
2.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.5.4 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Allergan Plc
2.6.1 Allergan Plc Details
2.6.2 Allergan Plc Major Business
2.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.6.4 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Novo Nordisk A/S
2.7.1 Novo Nordisk A/S Details
2.7.2 Novo Nordisk A/S Major Business
2.7.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.7.4 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Boehringer Ingelheim
2.8.1 Boehringer Ingelheim Details
2.8.2 Boehringer Ingelheim Major Business
2.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.8.4 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Pfizer Inc
2.9.1 Pfizer Inc Details
2.9.2 Pfizer Inc Major Business
2.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
2.9.4 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Breakdown Data by Manufacturer
3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in NASH (Non-alcoholic Steatohepatitis) Biomarkers
3.4 Market Concentration Rate
3.4.1 Top 3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturer Market Share in 2021
3.4.2 Top 6 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturer Market Share in 2021
3.5 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region
4.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Region (2017-2028)
4.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2017-2028)
4.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028)
4.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028)
4.4 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028)
4.5 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028)
4.6 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028)
5 Market Segment by Type
5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Type (2017-2028)
5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2028)
5.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Application (2017-2028)
6.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2028)
6.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
7.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
7.3 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
7.3.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2017-2028)
7.3.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
8.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
8.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
8.3.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2017-2028)
8.3.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
9.2 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
9.3 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Region
9.3.1 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
10.2 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
10.3 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
10.3.1 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2017-2028)
10.3.2 South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2028)
11.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2028)
11.3 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country
11.3.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of NASH (Non-alcoholic Steatohepatitis) Biomarkers and Key Manufacturers
12.2 Manufacturing Costs Percentage of NASH (Non-alcoholic Steatohepatitis) Biomarkers
12.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Process
12.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Typical Distributors
13.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. GENFIT SA Basic Information, Manufacturing Base and Competitors
Table 4. GENFIT SA Major Business
Table 5. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 6. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Gilead Sciences, Inc. (GILD) Basic Information, Manufacturing Base and Competitors
Table 8. Gilead Sciences, Inc. (GILD) Major Business
Table 9. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 10. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 12. AstraZeneca Major Business
Table 13. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 14. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 16. Novartis AG Major Business
Table 17. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 18. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 20. Bristol-Myers Squibb Company Major Business
Table 21. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 22. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Allergan Plc Basic Information, Manufacturing Base and Competitors
Table 24. Allergan Plc Major Business
Table 25. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 26. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 28. Novo Nordisk A/S Major Business
Table 29. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 30. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 32. Boehringer Ingelheim Major Business
Table 33. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 34. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 36. Pfizer Inc Major Business
Table 37. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product and Services
Table 38. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 40. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 41. Market Position of Manufacturers in NASH (Non-alcoholic Steatohepatitis) Biomarkers, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 42. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity by Company, (K Units): 2020 VS 2021
Table 43. Head Office and NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Site of Key Manufacturer
Table 44. NASH (Non-alcoholic Steatohepatitis) Biomarkers New Entrant and Capacity Expansion Plans
Table 45. NASH (Non-alcoholic Steatohepatitis) Biomarkers Mergers & Acquisitions in the Past Five Years
Table 46. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2017-2022) & (K Units)
Table 47. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2023-2028) & (K Units)
Table 48. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2017-2022) & (USD Million)
Table 49. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2023-2028) & (USD Million)
Table 50. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
Table 51. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
Table 52. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2017-2022) & (USD Million)
Table 53. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2023-2028) & (USD Million)
Table 54. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2017-2022) & (USD/Unit)
Table 55. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2023-2028) & (USD/Unit)
Table 56. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
Table 57. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
Table 58. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2017-2022) & (USD Million)
Table 59. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2023-2028) & (USD Million)
Table 60. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2017-2022) & (USD/Unit)
Table 61. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2023-2028) & (USD/Unit)
Table 62. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2022) & (K Units)
Table 63. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2023-2028) & (K Units)
Table 64. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2022) & (USD Million)
Table 65. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2023-2028) & (USD Million)
Table 66. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
Table 67. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
Table 68. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
Table 69. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
Table 70. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2022) & (K Units)
Table 71. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2023-2028) & (K Units)
Table 72. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2022) & (USD Million)
Table 73. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2023-2028) & (USD Million)
Table 74. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
Table 75. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
Table 76. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
Table 77. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
Table 78. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2017-2022) & (K Units)
Table 79. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2023-2028) & (K Units)
Table 80. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2017-2022) & (USD Million)
Table 81. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2023-2028) & (USD Million)
Table 82. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
Table 83. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
Table 84. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
Table 85. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
Table 86. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2017-2022) & (K Units)
Table 87. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2023-2028) & (K Units)
Table 88. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2017-2022) & (USD Million)
Table 89. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2023-2028) & (USD Million)
Table 90. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
Table 91. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
Table 92. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
Table 93. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
Table 94. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2017-2022) & (K Units)
Table 95. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2023-2028) & (K Units)
Table 96. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2017-2022) & (USD Million)
Table 97. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2023-2028) & (USD Million)
Table 98. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2017-2022) & (K Units)
Table 99. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2023-2028) & (K Units)
Table 100. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2017-2022) & (K Units)
Table 101. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2023-2028) & (K Units)
Table 102. NASH (Non-alcoholic Steatohepatitis) Biomarkers Raw Material
Table 103. Key Manufacturers of NASH (Non-alcoholic Steatohepatitis) Biomarkers Raw Materials
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. NASH (Non-alcoholic Steatohepatitis) Biomarkers Typical Distributors
Table 107. NASH (Non-alcoholic Steatohepatitis) Biomarkers Typical Customers
List of Figures
Figure 1. NASH (Non-alcoholic Steatohepatitis) Biomarkers Picture
Figure 2. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type in 2021
Figure 3. Serum Biomarkers
Figure 4. Hepatic Fibrosis Biomarkers
Figure 5. Apoptosis Biomarkers
Figure 6. Oxidative Stress Biomarkers
Figure 7. Others
Figure 8. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application in 2021
Figure 9. Pharma & CRO Industry
Figure 10. Hospitals
Figure 11. Diagnostic Labs
Figure 12. Academic Research Institutes
Figure 13. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (2017-2028) & (K Units)
Figure 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (2017-2028) & (USD/Unit)
Figure 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity (2017-2028) & (K Units)
Figure 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Production Capacity by Geographic Region: 2022 VS 2028
Figure 19. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers
Figure 20. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints
Figure 21. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Trends
Figure 22. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Manufacturer in 2021
Figure 23. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Manufacturer in 2021
Figure 24. NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 25. Top 3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturer (Revenue) Market Share in 2021
Figure 26. Top 6 NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturer (Revenue) Market Share in 2021
Figure 27. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2017-2028)
Figure 28. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2017-2028)
Figure 29. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (USD Million)
Figure 30. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (USD Million)
Figure 31. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (USD Million)
Figure 32. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (USD Million)
Figure 33. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2017-2028) & (USD Million)
Figure 34. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
Figure 35. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2017-2028)
Figure 36. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Type (2017-2028) & (USD/Unit)
Figure 37. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
Figure 38. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2017-2028)
Figure 39. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Price by Application (2017-2028) & (USD/Unit)
Figure 40. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
Figure 41. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
Figure 42. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2017-2028)
Figure 43. North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2017-2028)
Figure 44. United States NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
Figure 48. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
Figure 49. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2017-2028)
Figure 50. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2017-2028)
Figure 51. Germany NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2017-2028)
Figure 59. Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2017-2028)
Figure 60. China NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
Figure 67. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
Figure 68. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2017-2028)
Figure 69. South America NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2017-2028)
Figure 70. Brazil NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2017-2028)
Figure 73. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2017-2028)
Figure 74. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2017-2028)
Figure 75. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2017-2028)
Figure 76. Turkey NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Egypt NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. South Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Manufacturing Cost Structure Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers in 2021
Figure 81. Manufacturing Process Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers
Figure 82. NASH (Non-alcoholic Steatohepatitis) Biomarkers Industrial Chain
Figure 83. Sales Channel: Direct Channel vs Indirect Channel
Figure 84. Methodology
Figure 85. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ NASH（非アルコール性脂肪性肝炎）バイオマーカーの世界市場2022：血清バイオマーカー、肝線維症バイオマーカー、アポトーシスバイオマーカー、酸化ストレスバイオマーカー、その他(Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界の非アルコール性脂肪肝炎（NASH）バイオマーカー市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆